Hemogenyx Pharmaceuticals PLC (LSE:HEMO) — Market Cap & Net Worth
Market Cap & Net Worth: Hemogenyx Pharmaceuticals PLC (HEMO)
Hemogenyx Pharmaceuticals PLC (LSE:HEMO) has a market capitalization of $417.48K (GBX3.43 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30981 globally and #942 in its home market, demonstrating a -8.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemogenyx Pharmaceuticals PLC's stock price GBX640.00 by its total outstanding shares 5361267 (5.36 Million). See HEMO capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Hemogenyx Pharmaceuticals PLC Market Cap History: 2015 to 2026
Hemogenyx Pharmaceuticals PLC's market capitalization history from 2015 to 2026. Data shows growth from $2.45K to $417.48K (62.38% CAGR).
Hemogenyx Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemogenyx Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.36x
Hemogenyx Pharmaceuticals PLC's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.45K | $6.85K | -$180.88K | 0.36x | N/A |
Competitor Companies of HEMO by Market Capitalization
Companies near Hemogenyx Pharmaceuticals PLC in the global market cap rankings as of August 7, 2026.
Key companies related to Hemogenyx Pharmaceuticals PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Hemogenyx Pharmaceuticals PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Hemogenyx Pharmaceuticals PLC's market cap moved from $2.45K to $ 417.48K, with a yearly change of 62.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX417.48K | +11.89% |
| 2025 | GBX373.12K | +41.23% |
| 2024 | GBX264.19K | +17508.70% |
| 2023 | GBX1.50K | +73.58% |
| 2022 | GBX864.31 | -23.19% |
| 2021 | GBX1.13K | -82.12% |
| 2020 | GBX6.29K | +394.87% |
| 2019 | GBX1.27K | -7.14% |
| 2018 | GBX1.37K | -16.00% |
| 2017 | GBX1.63K | -33.33% |
| 2015 | GBX2.45K | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Hemogenyx Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $417.48K USD |
| MoneyControl | $417.48K USD |
| MarketWatch | $417.48K USD |
| marketcap.company | $417.48K USD |
| Reuters | $417.48K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more